Guggenheim raised the firm's price target on Nautilus Biotechnology to $4 from $2.50 and keeps a Buy rating on the shares. Every aspect of the Q4 report firms up Nautilus' foundation, showing line of sight to revenue, "albeit modest," this year and in 2027, the analyst tells investors in a post-earnings note.
